Potential role of targeted therapies in the treatment of triple-negative breast cancer

QR Code

Potential role of targeted therapies in the treatment of triple-negative breast cancer

Breast cancer is the most common cancer type that affects women and is the major cause of morbidity and mortality. Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype and accounts for 10–20% of all breast cancer cases. TNBC is commonly characterized by the absence of estrogen...

Full description

Bibliographic Details
Main Authors:	Jia, L., Shanmugam, M., Sethi, Gautam, Bishayee, A.
Format:	Journal Article
Published:	2016
Online Access:	http://hdl.handle.net/20.500.11937/7644

Similar Items

Targeted delivery of vitamin E TPGS based nanomedicine for treatment of triple negative breast cancer
by: Rajaletchumy, Veloo Kutty
Published: (2015)

Triple negative breast cancer in Asia: An insider's view
by: Wang, C., et al.
Published: (2018)

Recent advances in nanotheranostics for triple negative breast cancer treatment
by: Thakur, Vikram, et al.
Published: (2019)

The identification of targeting peptides and tumour associated antigens for the treatment and early detection of triple negative breast cancer
by: Wilde, Megan
Published: (2023)

The role of HOXA5 in triple-negative breast cancer (TNBC)
by: Mahmoud, Rinad
Published: (2021)

Wnt signaling in triple-negative breast cancer
by: Pohl, S., et al.
Published: (2017)

In silico investigations and potential approaches of Tectona grandis via targeting MMP-9 for triple negative breast cancer
by: Permana, Sofy, et al.
Published: (2024)

Potential role of genipin in cancer therapy
by: Shanmugam, M., et al.
Published: (2018)

Investigations of bioresponsive polymers in triple negative breast cancers
by: Monteiro, Patricia
Published: (2019)

The role of sodium driven bicarbonate transporters in triple negative breast cancer metastasis
by: Carroll, Christopher
Published: (2020)

Profiling of gene and exosomal microRNA as therapy targets and biomarkers of cisplatin resistance in triple negative breast cancer stem cell-like subpopulation
by: Koh, May Zie
Published: (2021)

Integrative molecular and pathologic profiling of triple negative breast cancer
by: Alsaleem, Mansour
Published: (2021)

Passerini multicomponent reaction: a versatile synthesis of nanomedicines for triple negative breast cancer treatment
by: Travanut, Alessandra
Published: (2021)

The role of resveratrol in cancer therapy
by: Ko, J., et al.
Published: (2017)

Targeted inhibition of tumor proliferation, survival, and metastasis by pentacyclic triterpenoids: Potential role in prevention and therapy of cancer
by: Shanmugam, M., et al.
Published: (2012)

The clonal and mutational evolution spectrum of primary triple-negative breast cancers
by: Shah, S., et al.
Published: (2012)

Ursolic acid in cancer prevention and treatment: Molecular targets, pharmacokinetics and clinical studies
by: Shanmugam, M., et al.
Published: (2013)

A clinicopathologic study on triple-negative breast cancer patients: HUSM experience
by: Saidin, Usman Sani
Published: (2011)

Genetic determinants of TAC chemotherapy response in triple negative breast cancer patients
by: Aziz, Ahmad Aizat Abdul
Published: (2018)

The association of ICAM-1 detected by immunohistochemical staining with triple negative and non-triple negative breast carcinoma
by: Chong, Choi Yen, et al.
Published: (2019)

Synthesis of small molecules targeting paclitaxel-induced MyD88 expression in triple-negative breast cancer cell lines
by: Khor, Poh Yen, et al.
Published: (2021)

Therapeutic potential of albumin nanoparticles encapsulated visnagin in MDA-MB-468 triple-negative breast cancer cells
by: Alsrhani, Abdullah, et al.
Published: (2023)

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
by: Cameron, David, et al.
Published: (2013)

Calpain system protein expression in basal-like and triple-negative invasive breast cancer
by: Storr, Sarah J., et al.
Published: (2012)

Apoptosis and cell cycle mechanisms of ampelopsin E on triple negative breast cancer cells
by: Abd Rahman, Napsiah
Published: (2017)

Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma
by: Swamy, S., et al.
Published: (2016)

PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers
by: Chen, L., et al.
Published: (2017)

Mediation of triple-negative breast cancer cell fate via cellular redox and Wnt signalling
by: Pohl, Sebastian Öther-Gee
Published: (2018)

Systematic review on the efficacy and safety of ixabepilone-based chemotherapy regimen in triple-negative breast cancer
by: Azizah, Maghfira Rahma, et al.
Published: (2024)

Role of genetic variations of abc (abcb1, abcc1 and abcg2) on triple negative breast cancer susceptibility risk
by: Ing, Yeoh Hao
Published: (2024)

Ampelopsin E reduces the invasiveness of the triple negative breast cancer cell line, MDA-MB-231
by: Tieng, Francis Yew Fu, et al.
Published: (2019)

PARP inhibitor combinations with Olaparib for synergistic efficacy in Olaparib-resistant triple-negative breast cancer cells
by: Yusoh, Nur Aininie
Published: (2023)

Role of calpain in breast cancer and regulation of therapeutic response to targeted treatment
by: Pu, Xuan
Published: (2016)

Polyadenylation as a target for the treatment of breast cancer
by: Thiyab, Asraa
Published: (2025)

Immunomodulatory potential of Clinacanthus nutans extracts in the co-culture of triple-negative breast cancer cells, MDA-MB-231, and THP-1 macrophages
by: Nordin, Fariza Juliana, et al.
Published: (2021)

High CD4+/CD8+ Intratumour Ratio is associated with favourable outcome in triple-negative Breast Cancer
by: Thian, Q.Z., et al.
Published: (2022)

Effects of ampelopsin E towards the invasiveness of triple negative breast cancer cell line, MDA-MB-231
by: Tieng, Francis Yew Fu
Published: (2019)

The molecular mechanism of the anticancer effect of Artonin E in MDA-MB 231 triple negative breast cancer cells
by: Etti, Imaobong Christopher, et al.
Published: (2017)

Targeting transcription factor STAT3 for cancer prevention and therapy.
by: Chai, E., et al.
Published: (2015)

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer
by: Dent, R., et al.
Published: (2013)